DDInter351 DDInter1658
An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022]
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Chloramphenicol {u} (Compound) binds {v} (Gene) CYP3A5
Chloramphenicol {u} (Compound) upregulates {v} (Gene) CCNH
Chloramphenicol {u} (Compound) is included by {v} (Pharmacologic Class) Amphenicols
Chloramphenicol {u} (Compound) downregulates {v} (Gene) USP22
Chloramphenicol {u} (Compound) causes {v} (Side Effect) Angioedema
Chloramphenicol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Chloramphenicol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elotuzumab
Chloramphenicol {u} may lead to a major life threatening interaction when taken with {v} Flibanserin
Chloramphenicol (Compound) binds CYP3A5 (Gene)
Chloramphenicol (Compound) upregulates CCNH (Gene)
Chloramphenicol (Compound) is included by Amphenicols (Pharmacologic Class)
Chloramphenicol (Compound) downregulates USP22 (Gene)
Chloramphenicol (Compound) causes Angioedema (Side Effect)
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Donepezil
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Chloramphenicol may lead to a major life threatening interaction when taken with Flibanserin